Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.01 (market cap $9.43B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.95. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| BIO | JEPQ | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $356.25 | $61.46 |
52-Week Low | $241.71 | $53.77 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
JEPQ trades at $60.01, up 0.55% today, with a bullish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with an options income strategy, generating monthly distributions. Recent news highlights its role in retirement income portfolios but notes tax implications for distributions. Key support sits at $59, with resistance at $60.
The outlook remains positive for income-seeking investors, supported by institutional buying and media coverage. Risks include tax treatment of distributions and market volatility affecting the underlying Nasdaq holdings. Analyst sentiment is mixed due to high RSI levels suggesting potential overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
